Skip to main content
Help us understand how you use our websites. Take part in our 30 minute study now.

Cardiopulmonary exercise testing and echocardiographic exam: an useful interaction


Cardiopulmonary exercise test (CPET) is a functional assessment that helps to detect disorders affecting the system involved in oxygen transport and utilization through the analysis of the gas exchange during exercise. The clinical application of CPET is various, it including training prescription, evaluation of treatment efficacy and outcome prediction in a broad spectrum of conditions. Furthermore, in patients with shortness of breath it provides pivotal information to bring out an accurate differential diagnosis between physical deconditioning, cardiopulmonary disease and muscular diseases. Modern software allows the breath-by-breath analysis of the volume of oxygen intake (VO2), volume of carbon dioxide output (VCO2) and expired air (VE). Through this analysis, CPET provides a series of additional parameters (peak VO2, ventilatory threshold, VE/VCO2 slope, end-tidal carbon dioxide exhaled) that characterize different patterns, helping in diagnosis process. Limitations to the routine use of CPET are mainly represented from the lack of measurement standardization and limited data from randomized multicentric studies. The integration of CPET with exercise stress echocardiography has been recently introduced in the clinical practice by integrating the diagnostic power offered by both the tools. This combined approach has been demonstrated to be valuable for diagnosing several cardiac diseases, including heart failure with preserved or reduced ejection fraction, cardiomyopathies, pulmonary arterial hypertension, valvular heart disease and coronary artery disease. Future investigations are needed to further promote this intriguing combination in the clinical and research setting.

Peer Review reports


Cardiopulmonary exercise testing (CPET) allows the evaluation of gas exchange throughout exercise, providing a detailed description about the system involved in both O2 transport and its utilization during exercise. This information has a critical practical relevance in different clinical settings since CPET provides data on functional capacity, training prescription [1], treatment efficacy and outcome prediction in a broad spectrum of conditions [2,3,4]. Now days, this test has achieved relevant impact in clinical decision making [5], obtaining class I recommendation for evaluating exertion dyspnoea of uncertain cause and stratifying cardiac risk before heart transplant in heart failure [6]. Shortness of breath may represent the expression of different circumstances, ranging from physical deconditioning to cardiopulmonary or muscular diseases. When first line exams such as standard exercise testing, echocardiography or spirometry, have not identified a definite cause of this clinical symptom, CPET should be considered. Given its high negative predictive value [7], normal CPET response may exclude clinically significant heart diseases. This technique remains largely underused in the clinical setting, mainly in relation with the poor knowledge of its evidences and potentialities. Moreover, little is known about its interaction with echocardiography in diagnosing and managing heart failure patients.

Accordingly, the purpose of this review was to spread awareness about the distinct clinical impact of CPET and its interaction with the echocardiographic exam findings, a combination which can substantially improve the patient’s management in a variety of different conditions.

Methodology of CPET

CPET can be performed on both cycle-ergometer or treadmill according to the individual laboratory availability. Data on ventilation and respiratory gas exchange can be collected by using a facemask or a mouthpiece. CPET is usually carried out using an incremental-work approach based on a ramp-like protocol. Ramp protocol consists in a gradual raise of work rate within each minute during the exercise [8], avoiding abrupt increases occurring in step-like protocol. By using this approach, a more linear and physiological response to the test is obtained, providing a more readable results. Accordingly, CPET allows to precisely determine at which level of effort the symptoms occur, and whether this happens before or after the anaerobic threshold. Frequently, a 10-watts per minute (W/min) ramp protocol with 1 W per 6 s work rate increment is used in the clinical setting (Fig. 1).

Fig. 1

Oxygen uptake pattern during CPET ramp protocol. The blue dotted line represents a normal pattern. The red dotted line is representative of a patient with heart failure with a resulting reduced peak VO2

CPET variables interpretation

Modern softwares allow the breath-by-breath analysis of the volume of oxygen intake (VO2), volume of carbon dioxide output (VCO2) and expired air (VE). Through this analysis, CPET provides a series of parameters that characterize different patterns, helping in diagnosis process. Table 1 reports common parameters resulting from CPET.

Table 1 Parameters of CPET and normal values

VO2 is a pivotal parameter that embodies insights on both cardiac and pulmonary function as an expression of the Fick’s principle according to which VO2 corresponds to cardiac output multiplied by the artero-venous gradient [C(a-v)O2]. During ramp-like exercise VO2 increases exponentially up to a steady state corresponding to peak exercise. Three abnormal patterns of VO2 curve can be observed during ramp test. The first is the upward shift of the overall curve due to higher request of O2 consumption as it happens in obese patients. The second is a relatively shallow slope secondary to reduced oxidative enzyme activity in skeletal muscle due to chronic heart failure or deconditioning. The third pattern, known as “the hockey stick” pattern, i.e. ΔVO2/Δwork rate (WR) flattening, is represented by a sharp and sudden interruption of the slope anticipating the expected peak intensity. The sudden interruption of oxygen uptake during the exercise is due to the exhaustion of the patient’s energy reserve, which is typical of myocardial ischemia, diastolic or systolic dysfunction, valve regurgitation or of conditions in which the exercise related heart rate increase is blunted by beta-blockers [9].

Peak VO2 corresponds to the peak values of oxygen consumption at maximal effort, expressed by litres of oxygen per minute or indexed as millilitres of oxygen per kilogram of body weight per minute. It describes the maximal amount of energy produced by aerobic metabolism. Peak VO2 can be reported also as a percentage of predicted peak VO2. Predicted pre-testpeak VO2changes according to age and sex have been established, they being lower in the elderlyand in female patients [10, 11].

Ventilatory threshold (VT) corresponds to the point at which muscle oxygen demand is higher than oxygen delivery, so that the metabolism switches from aerobic to anaerobic. This parameter is usually indirectly derived from VO2, VCO2 and VE data, but can even be directly obtained measuring blood lactate levels. In healthy subjects the ventilatory threshold usually occurs in between 40 and 60% of peak VO2 [12]. Values of ventilatory threshold are lower than those predicted in case of cardiopulmonary disease or deconditioning. When metabolism becomes mainly anaerobic, the lactic acid produced at this point is buffered by bicarbonate anions, thus increasing the level of carbon dioxide exhaled. As a result, the ratio between exhaled CO2 and the oxygen uptake (peak respiratory exchange ratio) increases. Therefore, values of peak respiratory exchange ratio above 1.1 during exercise identify a consistent anaerobic metabolism activation. Additionally, since high VCO2/VO2 ratio is an expression of the exercise burden, this parameter is also used to double-check if the effective patient’s motivation is enough elevated to accomplish the maximal effort (only in presence of an elevated VCO2/VO2, a stress test can be considered to be maximal). Exercise interruption at a peak respiratory exchange ratio lower than 1.0 can express limitation in muscle strain, possibly hiding hemodynamic or ventilatory impairment.

VE/VCO2 slope represents the ventilatory efficiency, measuring the amount of exhaled air needed to expel one litre of carbon dioxide. Regularly, VE/VCO2 slope increases with age and is altered by ventilation perfusion mismatch following cardiopulmonary or metabolic disease. Worthy of note, among the different CPET parameters, VE/VCO2 appeared to be the only one capable of predicting prognosis in patients with diastolic heart failure [13] (Fig. 2).

Fig. 2

The VE/VCO2 slope during ramp incremental exercise in a normal subject (a) and in a patient with mild (b) and moderate (c) heart failure. A reduced ventilatory efficiency is present in heart failure expressed by a steeper VE/Vco2 slope when compared with that of a normal subject. VE = Ventilation; VCO2 = Volume of exhaled carbon dioxide; HF = Heart failure patient

The partial pressure of end-tidal carbon dioxide exhaled (end-tidal PCO2) identifies the perfusion state, or more precisely is a parameter of ventilation/perfusion mismatch (V/Q mismatch). It inversely correlates with cardiac output [14], being markedly reduced in conditions of circulatory impairment, as it occurs in chronic heart failure because of a higher V/Q mismatch. However, end-tidal PCO2can be reduced also in respiratory dysfunction in which alveolar dead space is increased, such as pulmonary emphysema or parenchymal lung diseases, independently of the state of cardiac function [15].

Other quantitative parameters can be analysed during CPET, such as oscillatory ventilation expressing ventilation fluctuation during exercise. Oscillatory ventilation can be due either to ventilatory or hemodynamic instability [16]. Oscillatory ventilation pattern is recognized when it involves more than 60% of the exercise duration with 15% of variation compared to ventilation values at rest [6]. The oxygen uptake efficiency slope (OUES) is derived from the relationship between VO2 and the log transformation of VE and expresses the ventilatory requirement for a given O2 [6].

Clinical applications

Exercise prescription

CPET is considered an accurate method to assess aerobic performance for both healthy individuals and patients with cardiovascular and/or respiratory diseases, consistently driving the exercise prescription [17]. Pivotal data in exercise prescription are heart rate (HR) and VT. The exercise performed below VT is considered the sub-maximal level tolerated by an individual patient for a sustained amount of time. Moreover, HR values at different points through the exercise are reported (i.e. HR at rest, HR at VT) in order to refine aerobic exercise prescriptions.

CPET in heart failure

Functional assessment measured by CPET gives pivotal information about maximal aerobic capacity, therapy management and exercise prescription in patients with chronic heart failure. In the majority of these patient, CPET shows reduced VO2, VT < 40% of the predicted VO2 curve, peak VO2 < 85%, increased VE/VCO2, but normal O2 saturation [18]. Of interest, peak VO2 < 14 mL/kg/min carries a poor prognosis, being considered as indication for heart transplant [19]. Combined all together, these parameters, along with wide oscillations in ventilation during exercise and low HR recovery during the first minute after peak stress, reflect the ventilatory and metabolic inefficiency and are of relevant impact on prognosis in heart failure patients [20]. A comprehensive analysis of these parameters can help in accurately predicting the mortality rate in these patients [21]. In a metanalysis of studies on patients with heart failure undergoing CPET, peak VO2, VE/VCO2 slope, OUES and periodic ventilation appeared to have a strong prognostic impact, predicting adverse cardiovascular events with odds ratios of 4.10 (CI: 3.16–5.33), 5.40 (CI: 4.17–6.99), 8.08 (CI: 4.19–15.58) and 5.48 (CI: 3.82–7.86), respectively [22]. Myers et al. produced a stratification score that integrates most of the above-mentioned parameters (Table 2). The score ranges from 0 to 20, with the first group (0–5) used as a reference. Patients with a score >  15 had a 3 years mortality of 12.2% [23]. Noteworthy, VT can be undetermined in patients with considerably reduced exercise tolerance, thus unidentifiable VT is also considered a negative prognostic factor in patients with end-stage heart failure [24]. Accordingly, CPET has class I recommendation and level A in patients with HFrEF being considered for heart transplantation or mechanical device implantation [6]. In heart failure with preserved ejection fraction (HFpEF), not only peak VO2, but also the percent-predicted peak VO2 appear not be able to predict adverse events, probably, because current algorithms work poorly in this clinical setting. However, VE/VCO2 has shown the capability of predicting adverse events [25, 26] In particular, a VE/VCO2 slope > 33.3 showed a sensitivity of 97% and a specificity of 40% in predicting mortality and cardiac-related hospitalization in patients left ventricular ejection fraction (LVEF) > 50% [13].

Table 2 Cardiopulmonary exercise test score (modified from Ref # 23)

CPET in differential diagnosis of dyspnoea

In the cases of unexplained dyspnoea, 4 different categories can be identified by combining CPET variables: cardiac, pulmonary, mixed and non-cardiopulmonary [27, 28]. Reduction in peak VO2 is seen in both respiratory, cardiac and metabolic disease. Mainly, patients with respiratory diseases show a significant drop (i.e.,> 4% on peak exertion) in O2 saturation and low breathing reserve (i.e.,< 20%) [29]. On the other hand, patients with exertion dyspnoea induced by cardiac diseases show reduced peak VO2, early VT, high VE/CO2 slope, reduced OUES [29]. Of note, OUES has gained a recognized prognostic value in patients undergoing submaximal exercise [6]. In both primary or thromboembolic pulmonary arterial hypertension (PAH), low peak VO2 and high VE/Vco2 ratio during exercise have demonstrated to be useful in establishing the severity of functional impairment [30]. Consistently, CPET can be of helpful for the physicians who must face patients complaining dyspnoea both in terms of differential diagnosis and symptoms classification. Table 3 summarizes abnormal CPET patterns in patients with dyspnoea.

Table 3 CPET variables in different causes of dyspnea

CPET in congenital heart disease

CPET provides an integrated evaluation of cardiac, pulmonary, and metabolic function and may be used to identify the source of exercise limitation in congenital heart disease. Because CPET measurements have also been associated with outcome in adults with congenital heart disease, CPET is now considered as an important prognostic indicator and also useful for surgical stratification in this population [31].

Integration of CPET and echocardiography

Heart failure

Exercise stress echocardiography (ESE) and CPET can be considered an intriguing combination, possibly providing fundamental information on differential diagnosis and therapeutic management in patients suffering for exertion dyspnoea in different clinical settings, mainly in patients complaining heart failure symptoms and valve heart disease. The combination CPET-ESE can non-invasively evaluate multiple aspects of the cardiovascular system, offering a more personalised O2 pathway analysis, which is otherwise obtainable only with invasive hemodynamic monitoring [32]. In this context, the CPET-ESE approach is particularly valuable in identifying non-cardiopulmonary causes of dyspnoea, which are mainly related to an impaired oxygen extraction (AVO2diff) [5]. Different authors have demonstrated that the effort intolerance observed in HFpEF and heart failure with mid range LVEF could be related to an impaired AVO2diff (peripheral component of Fick equation) and near-normal cardiac output [33,34,35].

In some patients, complaining exertion dyspnoea, in particular if hypertensive, the early stages of HFpEF cannot be always detectable by the sole echocardiographic exam at rest since the simple quantification of LVEF often fails to predict functional capacity. Under these circumstances, the combination of speckle tracking echocardiography and CPET may provide additional information. Global longitudinal strain (GLS) is reduced in parallel with a reduced peak VO2 response and was superior to LVEF in identifying patients with impaired peak VO2 [36]. A comprehensive non-invasive evaluation of LV diastolic function – performed according to standardized ASE/EACVI recommendations [37] - has also a proved a diagnostic impact in predicting functional capacity in patients with HFpEF [34]. Since patients with normal LV filling pressures or even normal LV diastolic function at rest may reveal elevated LV filling pressures during effort [37,38,39,40,41], diastolic stress testing is indicated when echo exam at rest does not explain the symptoms of heart failure or dyspnoea, especially with exertion [37]. An E/e’ ratio >  15 during exercise can be considered as an accurate marker of HFpEF in presence of cardiac symptoms [42,43,44,45]. Accordingly, the combination of CPET results, in particular VE/CO2 slope, and E/e’ ratio at peak stress may be highly demonstrative of HFpEF (Fig. 3) [46]. This is confirmed also in patients with ischemic heart failure in which E/e’ ratio at peak stress was the most useful parameter for identifying severe exercise intolerance, as indicated by peak oxygen uptake < 14 mL/kg/min (AUC of E/e’ ratio ≥ 18 = 0.92, sensitivity = 85.2%, specificity = 95.6%) [47]. Worthy of note, the integrated CPET-ESE approach proved to increase patient risk stratification also in HFrEF, thanks to possibility of directly studying both LV and right ventricular (RV) contractility [35, 48].

Fig. 3

Illustrative clinical case of combined CPET and stress echo approach in a patient affected by HFpEF. CPET analysis shows clear oscillatory patterns of minute ventilation (VE) (a) and reduced VE/VCO2 ratio (b). Echocardiographic exam at rest shows a preserved ejection fraction (c) and an E/e’ ratio in the normal range (e). At peak exercise the ejection fraction is normal (d) but E/e’ appears to be pathologically increased (f)

Valvular heart disease

Given the complicated relationships existing between hemodynamic changes from resting condition to peak exercise in patients with valvular disease, new protocols combining ESE and CPET may give detailed information to better face the challenge in developing optimal individualized therapy [49]. ESE associated with CPET can provide crucial information on exercise intolerance in asymptomatic patients with hemodynamically significant mitral regurgitation (MR). Reduced peak VO2 has an important prognostic value in patients with significant MR, although the mechanisms underlying this association are not well established. In this subset of patients, ESE can provide information about the hemodynamic response to effort by measuring mean pulmonary arterial pressure (PAPm), systolic pulmonary arterial pressure (PAPs), RV systolic function and cardiac output (CO). Recently, reduced values in pulmonary vascular reserve, measured by PAPm/CO slope, and in RV contractile reserve, expressed by tricuspid annulus plane systolic excursion (TAPSE)/PAPs changes between rest and peak effort, were found to predict a low peak VO2 response during effort. Accordingly, this association may explain the etiology of impaired exercise tolerance in patients affected by asymptomatic but significant MR. The combination of low pulmonary vascular reserve, impaired RV contractile reserve and low peak VO2 may also guide the optimal timing for mitral valve surgery [50]. Frequently, patients with mitral stenosis (MS) show reduced exercise tolerance that, in some cases, is out of proportion compared to the hemodynamic at rest [49]. It is conceivable that several factors could contribute to alter exercise response in MR. Indeed, a low peak exercise HR (chronotropic incompetence) and the absence of a significant rise in stroke volume (impaired contractile reserve), combined with a reduced respiratory reserve (restrictive lung function) have a critical impact on the exercise response in MS. Accordingly, by combining CPET with echocardiography it is possible to identify the different determinants of reduction of both exercise capacity and peak VO2, thus improving patient selection for targeted treatment. Of note, Laufer-Perl et al. demonstrated that in patients with moderate-to-severe MS, restrictive lung function, chronotropic incompetence and limited contractile reserve had a greater impact on symptoms compared to MS severity itself, as expressed by the transvalvular gradient and the mitral valve area [51].

Primary cardiomyopathies

Another possible combination of CPET and echocardiography involves cardiomyopathies and, in particular, the differential diagnosis with the athlete’s heart. Echocardiography is largely used for diagnosis of hypertrophic cardiomyopathy (HCM), it allowing to characterize a disproportionate increase of LV wall thickness and a reduction of LV end-diastolic diameter [51]. However, maximal wall thickness ranging between 13 and 15 represents a grey zone which can occur in 4% of males and more frequently in black athletes [52]. In addition, diagnostic accuracy of echocardiography is limited by the lack of clear cut-off points stratified by ethnicity, gender and sport types. CPET can help the echo approach to appropriately diagnosing HCM in athletes [52]. VO2max resulted to be substantially reduced in athletes with HCM than in healthy athletes; in particular, a pVO2 > 50 ml/kg/min or >  20% above the predicted maximum VO2 differentiated athlete’s heart from HCM [53]. These results could open unexplored horizons in order to refine echocardiographic diagnosis of HCM in athletes.

Pulmonary arterial hypertension

In chronic thromboembolic PAH, a fast and accurate diagnosis is pivotal for successful treatment. Clinical symptoms/signs may be nonspecific and risk factors not always detectable. Echocardiography is the recommended first-line diagnostic tool and guidelines recommend non invasively estimation of PAPs (by peak velocity of tricuspid regurgitation and atrio-ventricular pressure gradient) and detection of indirect signs of PAH (RV and right atrial dilation, RV systolic dysfunction corresponding to a reduced TAPSE and standard Doppler derived abnormalities of RV outflow tract) [54, 55]. CPET may be complementary and help to identify patients with milder abnormalities and chronic thromboembolic disease. Patients with impaired ventilation due to pulmonary arterial obstruction show elevated alveolar-capillary gradients of O2 and CO2 [56]. In a retrospective report, CPET was able to identify chronic thromboembolic PAH, despite normal echo exam [57]. It is also worthy of note that In patients symptomatic for dyspnea, the occurrence of ΔVO2/Δwork rate flattening, ie. the “hockey stick” pattern, demonstrated to reflect a significantly impaired functional phenotype whose major cardiac determinants are the excessive PAPs increase and the reduced TAPSE) [58].

Coronary artery disease

In the setting of coronary artery disease, the combination of ESE and CPET performed in 110 patients, allowed to discriminate between coronary circulatory disease and de-conditioning (i.e., a decrease in the responsiveness of heart muscle occurring after long periods of weightlessness and corresponding to a blood volume reduction and blood pooling in the legs upon return to normal conditions) [59]. In fact, multiple gas exchange parameters obtained by CPET were associated, despite with low sensitivity, with abnormal echo-Doppler derived stroke volume response to stress, and VE/VCO2 slope to peak VO2 ratio was the best discriminator (≥2.7: AUC 0.79, p < 0.0001). These findings demonstrate that in patients with borderline results, a combined stress-echo with CPET, measuring stroke volume and A-VO2 difference throughout effort may be helpful for diagnosing significant coronary artery disease. Furthermore, stress echo derived wall motion abnormalities of isolated coronary lesions other than anterior descending artery, may require particular effort due to poor endocardial visualization, particularly when dealing with significant lesion of the right coronary artery. Blunted physiological VO2 increase and plateau in HR response during CPET has demonstrated to be indicative of myocardial ischemia of right coronary artery, anticipating ECG abnormalities [60]. Hence, we can speculate that combined analysis of CPET pattern and wall motion abnormalities during ESE may improve the accuracy level in diagnosing right coronary artery stenosis.

Table 4 reports the main echo-derived systolic and diastolic measurement which can be combined with CPET parameters.

Table 4 ESE parameters and normal values


CPET is being increasingly applied together with echocardiography, in particular ESE, in order to combine functional and structural data. Its use may add crucial information to the echo exam, in particular during stress. The additional diagnostic value of this combined assessment has been demonstrated in multiple clinical settings, including heart failure, valvular heart disease, hypertrophic cardiomyopathy, chronic thromboembolic derived PAH and coronary artery disease. On the grounds of recognized evidences [23, 61], it is conceivable that CPET data combined with clinical, laboratory and echocardiographic measurements could very efficiently stratify prognosis in patients with cardiac diseases.

Availability of data and materials

Not applicable.


C(a-v)O2 :

Arterial-venous gradient


Cardiopulmonary exercise test


Exercise stress echocardiography


Hypertrophic cardiomyopathy


Heart failure with preserved ejection fraction


Heart rate


Left ventricular


Oxygen uptake efficiency slope


Pulmonary arterial hypertension


Pulmonary arterial mean pressure


Pulmonary arterial systolic pressure


Tricuspid annulus plane systolic excursion

VCO2 :

Volume of carbon dioxide output


Volume of expired air

VO2 :

Volume of oxygen intake


Ventilatory threshold


  1. 1.

    Vesterinen V, Nummela A, Heikura I, Laine T, Hynynen E, Botella J, Häkkinen K. Individual endurance training prescription with heart rate variability. Med Sci Sports Exerc. 2016;48:1347–54.

    PubMed  Article  PubMed Central  Google Scholar 

  2. 2.

    Corrà U, Piepoli MF, Adamopoulos S, Agostoni P, Coats AJ, Conraads V, et al. Cardiopulmonary exercise testing in systolic heart failure in 2014: the evolving prognostic role: a position paper from the committee on exercise physiology and training of the heart failure association of the ESC. Eur J Heart Fail. 2014;16:929–41.

    PubMed  Article  PubMed Central  Google Scholar 

  3. 3.

    Guazzi M, Arena R, Halle M, Piepoli MF, Myers J, Lavie CJ. 2016 focused update: clinical recommendations for cardiopulmonary exercise testing data assessment in specific patient populations. Circulation. 2016;133:e694–711.

    PubMed  Article  PubMed Central  Google Scholar 

  4. 4.

    Myers J. Applications of cardiopulmonary exercise testing in the management of cardiovascular and pulmonary disease. Int J Sports Med. 2005;26:S49.

    PubMed  Article  PubMed Central  Google Scholar 

  5. 5.

    Guazzi M, Bandera F, Ozemek C, Systrom D, Arena R. Cardiopulmonary exercise testing: what is the value ? J Am Coll Cardiol. 2017;70:1618–36.

    PubMed  Article  PubMed Central  Google Scholar 

  6. 6.

    Gibbons RJ, Balady GJ, Bricker JT, Chaitman BR, Fletcher GF, Froelicher VF, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 exercise testing guidelines). ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee to update the 1997 exercise testing guidelines). Circulation. 2002;106:1883–92.

    PubMed  Article  PubMed Central  Google Scholar 

  7. 7.

    Nusair S. Interpreting the incremental cardiopulmonary exercise test. Am J Cardiol. 2017;119:497–500.

    PubMed  Article  Google Scholar 

  8. 8.

    Myers J, Bellin D. Ramp exercise protocols for clinical and cardiopulmonary exercise testing. Sports Med. 2000;30:23–9.

    CAS  PubMed  Article  Google Scholar 

  9. 9.

    Adachi H. Cardiopulmonary Exercise Test. Int Heart J. 2017;58:654–65.

    CAS  PubMed  Article  Google Scholar 

  10. 10.

    Betik AC, Hepple RT. Determinants of VO2max decline with aging: an integrated perspective. Appl Physiol Nutr Metab. 2008;33:130–40.

    PubMed  Article  Google Scholar 

  11. 11.

    Astrand I. Aerobic work capacity in men and women with special reference to age. Acta Physiol Scand. 1960;49:1–9.

    CAS  Google Scholar 

  12. 12.

    Wasserman K, Hansen JE, Sue DY, Stringer WW, Whipp BJ. Normal values. In: Wasserman K, Hansen JE, Sue DY, Stringer WW, Sietsema KE, Sun X-G, Whipp BJ, editors. Principles of exercise testing and interpretation. Including pathophysiology and clinical applications. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2012. p. 154–80.

    Google Scholar 

  13. 13.

    Guazzi M, Myers J, Arena R. Cardiopulmonary exercise testing in the clinical and prognostic assessment of diastolic heart failure. J Am Coll Cardiol. 2005;46:1883–90.

    PubMed  Article  Google Scholar 

  14. 14.

    Jin X, Weil MH, Tang W, Povoas H, Pernat A, Xie J, Bisera J. End-tidal carbon dioxide as a noninvasive indicator of cardiac index during circulatory shock. Crit Care Med. 2000;28:2415–9.

    CAS  PubMed  Article  Google Scholar 

  15. 15.

    Matsumoto A, Itoh H, Eto Y, Kobayashi T, Kato M, Omata M, et al. End-tidal CO2 pressure decreases during exercise in cardiac patients: association with severity of heart failure and cardiac output reserve. J Am Coll Cardiol. 2000;36:242–9.

    CAS  PubMed  Article  Google Scholar 

  16. 16.

    Khoo MC, Kronauer RE, Strohl KP, Slutsky AS. Factors inducing periodic breathing in humans: a general model. J Appl Physiol. 1982;53:644–59.

    CAS  PubMed  Article  Google Scholar 

  17. 17.

    Araújo CG, Herdy AH, Stein R. Maximum oxygen consumption measurement: valuable biological marker in health and in sickness. Arq Bras Cardiol. 2013;100:e51–3.

    PubMed  Google Scholar 

  18. 18.

    Herdy AH, Uhnlerdorf D. Reference values for cardiopulmonary exercise testing for sedentary and active men and women. Arq Bras Cardiol. 2011;96:54–9.

    PubMed  Article  Google Scholar 

  19. 19.

    Mancini DM, Eisen H, Kussmaul W, Mull R, Edmunds LH Jr, Wilson JR. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation. 1991;83:778–86.

    CAS  PubMed  Article  Google Scholar 

  20. 20.

    Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2013;62:e147–239.

    PubMed  Article  Google Scholar 

  21. 21.

    Levy WC, Arena R, Wagoner LE, Dardas T, Abraham WT. Prognostic impact of the addition of ventilatory efficiency to the Seattle heart failure model in patients with heart failure. J Card Fail. 2012;18:614–9.

    PubMed  Article  Google Scholar 

  22. 22.

    Cahalin LP, Chase P, Arena R, Myers J, Bensimhon D, Peberdy MA, Ashley E, et al. A meta-analysis of the prognostic significance of cardiopulmonary exercise testing in patients with heart failure. Heart Fail Rev. 2013;18:79–94.

    PubMed  Article  Google Scholar 

  23. 23.

    Myers J, Oliveira R, Dewey F, Arena R, Guazzi M. Chase pet al. Validation of a cardiopulmonary exercise test score in heart failure. Circ Heart Fail. 2013;6:211–8.

    PubMed  Article  Google Scholar 

  24. 24.

    Agostoni P, Corrà U, Cattadori G, Veglia F, Battaia E, La Gioia R, et al. Prognostic value of indeterminable anaerobic threshold in heart failure. Circ Heart Fail. 2013;6:977–87.

    PubMed  Article  Google Scholar 

  25. 25.

    Malhotra R, Bakken K, D'Elia E, Lewis GD. Cardiopulmonary Exercise Testing in Heart Failure. JACC Heart Fail. 2016;4:607–16.

    PubMed  Google Scholar 

  26. 26.

    Guazzi M. Pulmonary hypertension in heart failure with preserved ejection fraction: pathophysiology and clinical perspectives. Circ Heart Fail. 2014;7:367–77.

    PubMed  Article  Google Scholar 

  27. 27.

    Wahls SA. Causes and evaluation of chronic dyspnea. Am Fam Physician. 2012;86:173–80.

    PubMed  Google Scholar 

  28. 28.

    Messner-Pellence P, Ximenes C, Brasileiro CF, Mercier J, Grolleau R, Prefaut CG. Cardiopulmonary exercise testing: determinants of dyspnea due to cardiac or pulmonary limitation. Chest. 1994;106:354–60.

    Article  Google Scholar 

  29. 29.

    Beaver WL, Wasserman K, Whipp BJ. On-line computer analysis and breath-by-breath graphical display of exercise function tests. J Appl Physiol. 1973;34:128–32.

    CAS  PubMed  Article  Google Scholar 

  30. 30.

    Weatherald J, Farina S, Bruno N, Laveneziana P. Cardiopulmonary exercise testing in pulmonary hypertension. Ann Am Thorac Soc. 2017;14(Supplement 1):S84–92.

    PubMed  Article  PubMed Central  Google Scholar 

  31. 31.

    Khan AM, Paridon SM, Kim YY. Cardiopulmonary exercise testing in adults with congenital heart disease. Expert Rev Cardiovasc Ther. 2014;12:863–72.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  32. 32.

    Houstis NE, Eisman AS, Pappagianopoulos PP, Wooster L, Bailey CS, Wagner PD, et al. Exercise intolerance in heart failure with preserved ejection fraction: diagnosing and ranking its causes personalized O2 pathway analysis. Circulation. 2018;137:148–61.

    PubMed  Article  PubMed Central  Google Scholar 

  33. 33.

    Dhakal BP, Malhotra R, Murphy RM, Pappagianopoulos PP, Baggish AL, Weiner RB, et al. Mechanisms of exercise intolerance in heart failure with preserved ejection fraction: the role of abnormal oxygen extraction. Circ Heart Fail. 2015;8:286–94.

    PubMed  Article  PubMed Central  Google Scholar 

  34. 34.

    Shimiaie J, Sherez J, Aviram G, Megidish R, Viskin S, Halkin A, et al. Determinants of effort intolerance in patients with heart failure: combined echocardiography and cardiopulmonary stress protocol. JACC Heart Fail. 2015;3:803–14.

    PubMed  Article  PubMed Central  Google Scholar 

  35. 35.

    Pugliese NR, Fabiani I, Santini C, Rovai I, Pedrinelli R, Natali A, et al. Value of combined cardiopulmonary and echocardiography stress test to characterize the hemodynamic and metabolic responses of patients with heart failure and mid-range ejection fraction. Eur Heart J Cardiovasc Imaging. 2019;20:828–36.

    PubMed  Article  Google Scholar 

  36. 36.

    Hasselberg NE, Haugaa KH, Sarvari SI, Gullestad L, Andreassen AK, Smiseth OA, et al. Left ventricular global longitudinal strain is associated with exercise capacity in failing hearts with preserved and reduced ejection fraction. Eur Heart J Cardiovasc Imaging. 2015;16:217–24.

    PubMed  Article  PubMed Central  Google Scholar 

  37. 37.

    Nagueh SF, Smiseth OA, Appleton CP, Byrd BF 3rd, Dokainish H, Edvardsen T, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2016;17:1321–60.

    PubMed  Article  Google Scholar 

  38. 38.

    Oh KJ, Park SJ, Nagueh FS. Established and novel clinical applications of the diastolic function assessment by echocardiography. Circ Cardiovasc Imaging. 2011;4:444–55.

    PubMed  Article  PubMed Central  Google Scholar 

  39. 39.

    Burgess IM, Jenkins C, Sharman EJ, Marwick TH. Diastolic stress echocardiography: hemodynamic validation and clinical significance of estimation of ventricular filling pressure with the exercise. J Am Coll Cardiol. 2006;47:1891–900.

    PubMed  Article  Google Scholar 

  40. 40.

    Ha JW, Oh JK, Pellikka PA, Ommen SR, Stussy VL, Bailey KR. Diastolic stress echocardiography: a novel noninvasive diagnostic test for diastolic dysfunction using supine bicycle exercise Doppler echocardiography. J Am Soc Echocardiogr. 2005;18:63–8.

    PubMed  Article  Google Scholar 

  41. 41.

    Agricola E, Oppizzi M, Pisani M, Margonato A. Stress echocardiography in heart failure. Cardiovasc Ultrasound. 2004;2:11.

    PubMed  PubMed Central  Article  Google Scholar 

  42. 42.

    Schiano-Lomoriello V, Santoro C, de Simone G, Trimarco B, Galderisi M. Diastolic bicycle stress echocardiography: normal reference values in a middle age population. Int J Cardiol. 2015;191:181–3.

    PubMed  Article  Google Scholar 

  43. 43.

    Paulus WJ, Tschöpe C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the heart failure and echocardiography associations of the European Society of Cardiology. Eur Heart J. 2007;28:2539–350.

    PubMed  Article  Google Scholar 

  44. 44.

    Nedeljkovic I, Banovic M, Stepanovic J, Giga V, Djordjevic-Dikic A, Trifunovic D, et al. Combined exercise stress echocardiography and cardiopulmonary exercise test for identification of masked heart failure with preserved ejection fraction in patients with hypertension. Eur J Prev Cardiol. 2016;23:71–7.

    PubMed  Article  Google Scholar 

  45. 45.

    Arques S, Roux E, Luccioni R. Current clinical applications of spectral tissue Doppler echocardiography (E/E' ratio) as a noninvasive surrogate for left ventricular diastolic pressures in the diagnosis of heart failure with preserved left ventricular systolic function. Cardiovasc Ultrasound. 2007;5:16.

    PubMed  PubMed Central  Article  Google Scholar 

  46. 46.

    van Riel AC, Opotowsky AR, Santos M, Rivero JM, Dhimitri A, Mulder BJ, et al. Accuracy of echocardiography to estimate pulmonary artery pressures with exercise: a simultaneous invasive-noninvasive comparison. Circ Cardiovasc Imaging. 2017;10:e005711.

    PubMed  PubMed Central  Google Scholar 

  47. 47.

    Podolec P, Rubís P, Tomkiewicz-Pajak L, Kopeć G, Tracz W. Usefulness of the evaluation of left ventricular diastolic function changes during stress echocardiography in predicting exercise capacity in patients with ischemic heart failure. J Am Soc Echocardiogr. 2008;21:834–40.

    PubMed  Article  Google Scholar 

  48. 48.

    Guazzi M, Villani S, Generati G, Ferraro OE, Pellegrino M, Alfonzetti E, et al. During exercise challenge in heart failure: pathophysiology and clinical phenotypes. JACC Heart Fail. 2016;4:625–35.

    PubMed  Article  Google Scholar 

  49. 49.

    Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Fleisher LA, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the Management of Patients with Valvular Heart Disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol. 2017;70:252–89.

    PubMed  Article  Google Scholar 

  50. 50.

    Utsunomiya H, Hidaka T, Susawa H, Izumi K, Harada Y, Kinoshita M, et al. Exercise-stress echocardiography and effort intolerance in asymptomatic/minimally symptomatic patients with degenerative mitral regurgitation combined invasive-non invasive hemodynamic monitoring. Circ Cardiovasc Imaging. 2018;11:e007282.

    PubMed  Article  Google Scholar 

  51. 51.

    Laufer-Perl M, Gura Y, Shimiaie J, Sherez J, Pressman GS, Aviram G, et al. Mechanisms of effort intolerance in patients with rheumatic mitral stenosis: combined echocardiography and cardiopulmonary stress protocol. JACC Cardiovasc Imaging. 2017;10:622–33.

    PubMed  Article  Google Scholar 

  52. 52.

    Galderisi M, Cardim N, D'Andrea A, Bruder O, Cosyns B, Davin L, et al. The multi-modality cardiac imaging approach to the Athlete's heart: an expert consensus of the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015;16(4):353.

    PubMed  Article  Google Scholar 

  53. 53.

    Sharma S, Elliott PM, Whyte G, Mahon N, Virdee MS, Mist B, et al. Utility of metabolic exercise testing in distinguishing hypertrophic cardiomyopathy from physiologic left ventricular hypertrophy in athletes. J Am Coll Cardiol. 2000;36:864–70.

    CAS  PubMed  Article  Google Scholar 

  54. 54.

    Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. The joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Heart J. 2016;37:67–119.

    PubMed  Article  Google Scholar 

  55. 55.

    Scheidl SJ, Englisch C, Kovacs G, Reichenberger F, Schulz R, Breithecker A, et al. Diagnosis of CTEPH versus IPAH using capillary to end-tidal carbon dioxide gradients. Eur Respir J. 2012;39:119–24.

    CAS  PubMed  Article  Google Scholar 

  56. 56.

    Serra W, Chetta A, Santilli D, Mozzani F, Dall'Aglio PP, Olivieri D, et al. Echocardiography may help detect pulmonary vasculopathy in the early stages of pulmonary artery hypertension associated with systemic sclerosis. Cardiovasc Ultrasound. 2010;8:25.

    PubMed  PubMed Central  Article  Google Scholar 

  57. 57.

    Held M, Grün M, Holl R, Hübner G, Kaiser R, Karl S. Cardiopulmonary exercise testing to detect chronic thromboembolic pulmonary hypertension in patients with normal echocardiography. Respiration. 2014;87:379–87.

    PubMed  Article  Google Scholar 

  58. 58.

    Bandera F, Generati G, Pellegrino M, Donghi V, Alfonzetti E, Gaeta M, et al. Role of right ventricle and dynamic pulmonary hypertension on determining DVO2/DVO2 work rate flattening: insights from cardiopulmonary exercise test combined with exercise echocardiography. Circ Heart Fail. 2014;7:782–90.

    PubMed  Article  Google Scholar 

  59. 59.

    Rozenbaum Z, Khouri S, Aviram G, Gura Y, Sherez J, Man A, et al. Discriminating circulatory problems from deconditioning: echocardiographic and cardiopulmonary exercise test analysis. Chest. 2017;151:431–40.

    PubMed  Article  Google Scholar 

  60. 60.

    Contini M, Andreini D, Agostoni P. Cardiopulmonary exercise test evidence of isolated right coronary artery disease. Int J Cardiol. 2006;113:281–2.

    PubMed  Article  Google Scholar 

  61. 61.

    Agostoni P, Corrà U, Cattadori G, Veglia F, La Gioia R, Scardovi AB, et al. Metabolic exercise test data combined with cardiac and kidney indexes, the MECKI score: a multiparametric approach to heart failure prognosis. Int J Cardiol. 2013;167:2710–8.

    PubMed  Article  Google Scholar 

Download references


Not applicable.


This work was supported by the International PhD Program in Cardiovascular Pathophysiology and Therapeutics CardioPath (to C.S., M.L., and R.S.).

Author information




CS, RS, RE are the major contributors in writing the manuscript. ML, VC and FR are responsible for the iconography in the text. MR, BT and MG revised it carefully and gave a significant scientific contribution to its content. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Maurizio Galderisi.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Santoro, C., Sorrentino, R., Esposito, R. et al. Cardiopulmonary exercise testing and echocardiographic exam: an useful interaction. Cardiovasc Ultrasound 17, 29 (2019).

Download citation


  • Cardiopulmonary exercise test
  • Echocardiography
  • Stress echo
  • Heart failure
  • Exercise prescription
  • Cardiomyopathies
  • Pulmonary hypertension
  • Coronary artery disease